Daily Bulletin

Men's Weekly

.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression

SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and...

Read more: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1...

Business News

Qualities to Check in an NDIS Provider

Everyone wants to live life with independence and dignity. For people with disabilities, achieving this often requires the right support. This is where NDIS providers play an important role. These pro...

Daily Bulletin - avatar Daily Bulletin

How Thorough Component Inspections Protect Your Supply Chain from Costly Failures

In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...

Daily Bulletin - avatar Daily Bulletin

3PL Logistics in Australia: Strengthening Supply Chains for Growing Businesses

Australia’s vast geography and diverse consumer markets make logistics a critical part of business success. As companies scale and customer expectations rise, many turn to 3pl logistics australia to...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business